Silence Therapeutics Plc - Amer (SLN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.27
- Estimate
- -$0.11
- Surprise
- -145.4%
- Score today
- 4.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Silence Therapeutics Plc - Amer (SLN) reported a wider loss than forecast — adjusted EPS of -$0.27 against the -$0.11 estimate (a 145.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SLN Sell at 4.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -145.4% surprise compares with a -85.0% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-15.1% upside)
- Quality below floor (3.4 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.78
- Stop
- $18.40
Risk check: RSI 86 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
SLN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.23B
- P/E (fwd)
- -52.1
- 52-week range
- $4.19–$19.86
- Off 52-week high
- 0.4%
- RSI (14)
- 86
- Volume vs avg
- 0.80×
- Score today
- 4.2/10